gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)
27 sept. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of two peer...
electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
26 sept. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
electroCore to Participate in the LD Micro Main Event XVI Conference
25 sept. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger,...
electroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference
21 sept. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger,...
electroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
07 sept. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger,...
Another Medicine to Stop Migraine in its Tracks – Zavzpret™ is Now Available, but Where will Neurologists use it?
17 août 2023 14h57 HE
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 17, 2023 (GLOBE NEWSWIRE) -- In February 2023, Pfizer published their positive Phase 3 clinical trial results for zavegepant (new brand name, Zavzpret™). At the time,...
electroCore Announces Second Quarter 2023 Financial Results
09 août 2023 16h05 HE
|
electroCore, Inc.
Record second quarter 2023 net sales of $3.6 million, an increase of approximately 65% over second quarter 2022 Company to host a conference call and webcast today, August 9, 2023 at 4:30 PM EDT ...
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
18 juil. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC
13 juil. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that ReletexTM by Reliefband,...
electroCore Provides Select Second Quarter 2023 Financial Guidance
11 juil. 2023 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today provided select preliminary...